COLL חוב כולל להון Collegium Pharmaceutical Inc

Collegium Pharmaceutical operates in a stable segment of strictly regulated analgesics. Reviewing the total debt-to-equity history on GURU.Markets, it is evident that the value 3.76 serves as the baseline leverage indicator. The business relies on an asset-light model utilizing contract manufacturing. High physician confidence confirms its status as an innovator that has developed safe, abuse-deterrent medications.

This indicator assesses the financial stability of Collegium Pharmaceutical (COLL) through the balance of debt and equity. The total debt-to-equity ratio is calculated as the ratio of all liabilities to equity, determining the degree of leverage. A decrease in this coefficient confirms an improvement in the balance sheet structure. Stable cash flow from high-margin analgesics allows for efficient debt servicing. The metric's dynamics objectively reflect the business's ability to self-finance.